← All stocks

abrdn Life Sciences Investors

HQL Net buying

CIK 0000884121 #5708 in the set updated 18 Sep 2026

Bought (120 mo)

$11.97M

out of their own pocket, the only kind of buying there is

Sold (120 mo)

$7.84M

$0.00 on a plan · $0.00 straight out of an exercise

Sold at will

$7.84M

39 of 39 sales

Net

+$4.13M

+$4.13M against sales at will

By person

10 insiders · 88 transactions

Insider

Role

Bought

Sold

Net

Holding

Worth

Change

Saba Capital Management, L.P. entity

10% owner

$10.87M (31)

$7.84M (39)

+$3.03M

2,837,633

$56.53M

+8.6%

OMSTEAD DANIEL R

President

$845.29K (7)

—

+$845.29K

197,518

$3.93M

+38.5%

Pittard Christian

Director

$133.75K (1)

—

+$133.75K

7,923

$157.83K

—

Kent Thomas M

Director

$27.35K (1)

—

+$27.35K

1,300

$25.90K

—

Maher Bill

Director

$23.56K (2)

—

+$23.56K

2,715

$54.09K

+154.9%

Goetz Kathleen

Director

$17.23K (3)

—

+$17.23K

1,771

$35.27K

+158.4%

DiMartino Rose

Director

$15.53K (1)

—

+$15.53K

1,000

$19.92K

—

Reit Todd

Director

$13.80K (1)

—

+$13.80K

1,000

$19.92K

—

Mahai Chris LaVictoire

Director

$10.50K (1)

—

+$10.50K

527

$10.50K

—

Bailey Jeffrey Allen

Director

$10.02K (1)

—

+$10.02K

580

$11.55K

—

No percentages here. abrdn Life Sciences Investors reports its share count only per share class, which the XBRL frames API does not carry.

Individual transactions

Nothing of that kind in this period.

What was left out

Form 4 filings counted 66

Amendments (4/A) skipped 0

Filings about a different issuer 0

Unreadable filings 0

Joint filings 44

Sales on a Rule 10b5-1 plan 0

Sales straight out of an exercise 0

Sales at will 39

Transactions with no price 0

Shares from compensation/vesting 0

History held since 29 Jan 2018